Skip to main content

Table 2 Proposed EORTC 1999 criteria for clinical and subclinical response assessment by PET-CT

From: Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer

Response Definition
Progressive metabolic disease An increase in 18FDG tumor SUV of greater than 25% within the tumor region defined on the baseline scan, visible increase in the extent of 18FDG tumor uptake (>20% in the longest dimension) or the appearance of new 18FDG uptake in metastatic lesions
Stable metabolic disease An increase in tumor 18FDG SUV of less than 25% or a decrease of less than 15% and no visible increase in extent of 18FDG tumor uptake (>20% in the longest dimension)
Partial metabolic response A reduction of a minimum of 15–25% in tumor 18FDG SUV after one cycle of chemotherapy, and greater than 25% after more than one treatment cycle
Complete metabolic response Complete resolution of 18FDG uptake within the tumor volume so that it was indistinguishable from surrounding normal tissue